

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number  
**WO 2004/055009 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 403/12**,  
403/14, 401/12, 401/14, 413/14, A61K 31/497, 31/496,  
31/5377, A61P 25/00, 3/10, 5/48, 15/18, 17/14

SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/SE2003/001957

(84) Designated States (*regional*): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:  
15 December 2003 (15.12.2003)

(25) Filing Language: English

## Declaration under Rule 4.17:

(26) Publication Language: English

(30) Priority Data:  
0203753-9 17 December 2002 (17.12.2002) SE

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,  
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG)

(71) Applicant (*for all designated States except US*): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BERG**, Ste-  
fan [SE/SE]; AstraZeneca R & D Södertälje, S-151  
85 Södertälje (SE). **HELLBERG**, Sven [SE/SE]; As-  
traZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-  
traZeneca AB, S-151 85 Södertälje (SE).


## Published:

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOBEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3



(I)

(57) Abstract: The present invention relates to new compounds of  
formula (I) wherein Z is N; Y is CONR<sup>5</sup>, NR<sup>5</sup>CO, SO<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>SO<sub>2</sub>,  
CH<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>, NR<sup>5</sup>CONR<sup>5</sup>, CH<sub>2</sub>CO, CO, O or CH<sub>2</sub>O; X is CH or N;  
P is phenyl or a 5 or 6 membered heteroaromatic ring containing one  
or more heteroatoms selected from N, O or S and said phenyl ring or 5  
or 6 membered heteroaromatic ring may optionally be fused with a 5  
or 6 membered saturated, partially saturated or unsaturated ring con-  
taining one or more atoms selected from C, N, O or S; Q is C<sub>1-6</sub>alkyl,  
C<sub>2-6</sub>alkenyl or C<sub>2-6</sub>alkynyl, a process for their preparation and new in-  
termediates used therein, pharmaceutical formulations containing said

therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective  
inhibiting effect at GSK3.